Lansoprazole

When ATH:
A02BC03

Characteristic.

The substituted benzimidazole derivative. Whitish-brown granular powder;. Sparingly soluble in ethyl alcohol, insoluble in hexane and water. Resistant to light, at 25 ° C decomposes in an acidic medium with T_1/2 0,5 h at pH 5,0 and 18 h - at pH 7,0.

Pharmacological action.
Antiulcer.

Application.

Neyazvennaya dyspepsia, gastric ulcer and duodenal ulcer, benign gastric ulcer, erosive and ulcerative esophagitis, reflux esophagitis, Zollinger - Ellison, infection Helicobacter pylori (combination therapy).

Contraindications.

Hypersensitivity, malignant neoplasms of the gastrointestinal tract, pregnancy (especially I trimester), lactation.

Restrictions apply.

Abnormal liver function, Age to 18 years (safety and effectiveness in these patients has been poorly studied), advanced age.

Pregnancy and breast-feeding.

I contraindicated in I trimester. In the second and third trimesters it is possible, if the expected benefit of therapy outweighs the potential risk to the fetus. At the time of treatment should stop breastfeeding.

Side effects.

From the digestive tract: diarrhea; less often - increase or decrease of appetite, nausea, stomach ache; rarely - constipation; in some cases - ulcerative colitis, gastrointestinal candidiasis, increase in liver enzymes (GOLD, IS, Alkaline phosphatase, gamma-glutamyl transferase, lactate dehydrogenase) and bilirubin.

From the nervous system and sensory organs: headache; rarely - a feeling of malaise, dizziness, drowsiness, depression, alarm.

From the respiratory system: rarely - a strong cough, pharyngitis, rhinitis, inflammation or infection of the upper respiratory tract.

Cardio-vascular system and blood: seldom-B19 (with hemorrhagic manifestations); in some cases - anemia.

For the skin: in some cases, photosensitization, erythema multiforme, alopecia.

Allergic reactions: skin rash.

Other: rarely - flu-like symptoms, myalgia.

Cooperation.

Decreases (on 10%) theophylline clearance. Sukralyfat of 30% reduces the bioavailability of (It should be an interval of 30-40 minutes between doses of these drugs). Antacids, containing magnesium hydroxide and algeldrat, while admission to lansoprazole may reduce the absorption of the latter. It can change the pH-dependent absorption of drugs, belonging to the groups of weak acids (slowdown) and bases (acceleration). It inhibits the absorption of ampicillin, digoksina, ketoconazole, цianokoʙalamina, iron salts. Possible interactions with drugs, metabolized with participation of cytochrome P450 enzyme system. Compatible with antipyrine, diazepamom, ibuprofen, Indomethacin, oral contraceptives, phenytoin, prednisolone, propranolol, varfarinom.

Overdose.

Symptoms: not disclosed (receiving a single dose 600 mg was not accompanied by clinical signs of overdose).

Treatment: recommended monitoring, carrying out maintenance and symptomatic therapy. Hemodialysis nyeeffyektivyen.

Dosing and Administration.

Inside, morning. Neyazvennaya dyspepsia: 15-30 mg / day for 2-4 weeks. Duodenal ulcer: 30 mg / day for 2-4 weeks. Gastric ulcer: 30-60 mg / day for 4-8 weeks. Erosive and ulcerative esophagitis: 30-60 mg / day for 4-8 weeks. Reflux esophagitis: 30 mg/day — 4 Sun. Zollinger - Ellison: Adjusted-dose, provides a level of acid below the basal 10 mmol / h. Инфицирование Helicobacter pylori: by 30 mg 2 times a day in the various schemes of the combined therapy of H. pylori.

Precautions.

Before and after the treatment required endoscopic examinations to exclude malignancies (lansoprazole can mask the symptoms and delay diagnosis). To use caution in patients with reduced liver function and in elderly patients (treatment is initiated with half doses, gradually increasing them to the recommended, but not more 30 mg / day). While the use of antacids should be used for their 1 hours before or after 1-2 h after administration of lansoprazole.

Cooperation